1. Pink Sheet
  2. >>Geography
  3. >>Europe

How Drug Preparations Undermine Europe’s Regulatory System

Genevieve Michaux and Luca Salernitano examine the complexities and concerns surrounding the flourishing practice of preparing medicines for patients by pharmacies and hospitals in the EU. They say it undermines the very essence of the EU drug evaluation system and the regimes adopted to incentivize the development of medicinal products for rare diseases and pediatric patients.

Pharmacist
There are concerns that preparations are undermining the EU drug approval system • Source: Shutterstock

Medicines prepared for patients by pharmacies or hospitals are becoming more and more common but they undermine the European drug review system and are detrimental to drug development for the smaller populations – rare disease and pediatric patients – in whom they have traditionally been used. 

About The Authors

Genevieve Michaux is a partner at the Brussels, Belgium, office of law firm Mayer Brown LLP, and Luca Salernitano is an associate at the same office. Email: gmichaux@mayerbrown.com.

Certain pharmacies can produce preparations in large quantities. This may not be a big threat to authorized prescription-only medicines designed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Plans For EU Biotech Act Shift Up A Gear

 
• By Eliza Slawther

Companies have until early November to respond to a public consultation from the European Commission on its planned Biotech Act, which it hopes will help unleash the potential of small and midsize enterprises in the bloc.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Vaccine Developers To Benefit From CEPI’s ‘World First’ Adjuvant ‘Matchmaking’ Service

 
• By Eliza Slawther

Selected vaccine developers will soon be able to use a new adjuvant “matchmaking” initiative that could help create more “effective, potent” vaccines against epidemic and pandemic threats, the Coalition for Epidemic Preparedness Innovations has said.

EMA Tackles Guidance Void As Proposals For External Controls Grow

 
• By Neena Brizmohun

The European Medicines Agency is working on defining when and how external controls can be accepted in clinical research. Among other things, it is looking at the planning, design, conduct, analysis and reporting of studies for which external controls are used.

More from Geography

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

AI In Clinical Research: Benefits Across The Board, But ‘Nirvana’ Still Out Of Reach

 
• By Vibha Sharma

Generative artificial intelligence tools, such as ChatGPT, have “democratized” AI, and contract research organizations are wholeheartedly embracing these tools, given their focus on efficiency, says Stephen Pyke, who chairs the AI committee at the Association of Clinical Research Organizations.

Japan Gives Global-First Recommendations To Taisho’s Vornorexant, Santen’s Sepetaprost

 
• By Lisa Takagi

Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.